Pharmaceutical

Novo Nordisk and Valo expand cardiometabolic drug partnership

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.

Jan 10, 2025 - 06:00
Novo Nordisk and Valo expand cardiometabolic drug partnership
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.
Read the original article

Tags:

Previous Article

Aspect Biosystems secures $115m to develop tissue therapeutics

Next Article

Sanofi taps Alloy Therapeutics for CNS antisense drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How are insurers handling the Alzheimer’s drug Leqembi and related scans?

STAT+: How are insurers handling the Alzheimer’s drug L...

Jul 12, 2023

Type 2 diabetes prevention programs can work at large scale, study finds

Type 2 diabetes prevention programs can work at large s...

Nov 15, 2023

Access to new tools to combat RSV in babies likely to prove challenging

Access to new tools to combat RSV in babies likely to p...

Oct 6, 2023